Drug intelligence / Profile preview

BAY2396217

Development stage: Preclinical
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

BAY2396217 is an investigational small molecule inhibitor developed by Bayer that targets **PTEFb (Positive Transcription Elongation Factor b)**, a master regulator of transcription. PTEFb includes cyclin-dependent kinase 9 (CDK9) and cyclin T complexes, and its inhibition is a novel approach explored in oncology. This drug is being studied as an anti-cancer therapy, leveraging the disruption of transcriptional processes necessary for tumor cell survival and proliferation[1].

Targets

CDK9 (Cyclin-dependent kinase 9)

Beyond the preview

Go deeper on BAY2396217.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY2396217.

Explore the full profile